USP <1031>
USP general test chapter for THE BIOCOMPATIBILITY OF MATERIALS USED IN DRUG CONTAINERS, MEDICAL DEVICES, AND IMPLANTS.
This chapter provides guidance on the identification and performance of procedures for evaluating the biocompatibility of drug containers, elastomeric closures, medical devices, and implants. Biocompatibility refers to the tendency of these products to remain biologically inert throughout the duration of their contact with the body. The biocompatibility testing procedures referenced in this chapter are designed to detect the nonspecific, biologically reactive, physical or chemical characteristics of medical products or the materials used in their construction. In combination with chemical assays, these biological procedures can be used to detect and identify the inherent or acquired toxicity of medical products prior to or during their manufacturing and processing.
Preclinical testing procedures to evaluate the safety of the elastomers, plastics, or other polymers used in the construction of medical products are referenced or described in the following general chapters: Injections and Implanted Drug Products 〈1〉, Biological Reactivity Tests, In Vitro 〈87〉, Biological Reactivity Tests, In Vivo 〈88〉, ▲Medical Devices—Bacterial Endotoxin and Pyrogen Tests 〈161〉▲ (CN 1-May-2019), Elastomeric Closures for Injections 〈381〉, Plastic Packaging Systems and Their Materials of Construction 〈661〉, Plastic Materials of Construction 〈661.1〉, and Plastic Packaging Systems for Pharmaceutical Use 〈661.2〉. Specific in vitro and in vivo testing procedures to evaluate the biocompatibility of medical products in patients are described under Biological Reactivity Tests, In Vitro 〈87〉 and under Biological Reactivity Tests, In Vivo 〈88〉